Table 3.
Correlation between the defined daily dose (DDD) and overall survival and progression-free survival by antibiotic class.
| Variables | Overall Survival | Progression-Free Survival | ||||||
|---|---|---|---|---|---|---|---|---|
| DDD, Mean ± SD | r | p-Value | DDD, Mean ± SD | r | p-Value | |||
| Survival n = 100 |
Death n = 40 |
Progression- Free Survival n = 35 |
Progressed Disease or Death n = 105 |
|||||
| Overall antibiotics | 13.1 ± 33.7 | 16.4 ± 33.3 | 0.15 | 0.068 | 15.7 ± 29.1 | 16.6 ± 34.7 | 0.01 | 0.896 |
| Anti-pseudomonal beta-lactamase inhibitor (piperacillin/tazobactam) |
1.7 ± 4.9 | 2.8 ± 6.5 | 0.27 | 0.001 | 2.2 ± 5.5 | 3.0 ± 6.8 | 0.05 | 0.576 |
| Anti-tuberculosis medications | - | 0.3 ± 3.9 | 0.13 | 0.114 | - | 0.3 ± 3.9 | 0.05 | 0.566 |
| Beta-lactamase inhibitors | 0.4 ± 2.7 | 0.3 ± 2.3 | −0.06 | 0.514 | 0.1 ± 0.5 | 0.4 ± 2.7 | 0.05 | 0.544 |
| Carbapenem (meropenem) | 0.5 ± 4.6 | 0.5 ± 4.2 | 0.02 | 0.810 | 1.3 ± 7.8 | 0.2 ± 1.9 | −0.11 | 0.196 |
| Cephalosporins, 1st generation | 0.7 ± 2.8 | 0.7 ± 2.8 | 0.01 | 0.891 | 0.2 ± 0.8 | 0.8 ± 3.1 | 0.09 | 0.280 |
| Cephalosporins, 2nd generation | 0.3 ± 1.3 | 0.3 ± 1.2 | −0.04 | 0.608 | 0.0 ± 0.2 | 0.4 ± 1.3 | 0.13 | 0.134 |
| Cephalosporins, 3rd generation | 1.6 ± 4.7 | 1.7 ± 4.5 | −0.05 | 0.595 | 2.3 ± 6.2 | 1.5 ± 3.8 | −0.07 | 0.392 |
| Cephalosporin, 4th generation (cefepime) |
- | 0.2 ± 2.0 | 0.13 | 0.114 | - | 0.2 ± 2.3 | 0.05 | 0.566 |
| Fluoroquinolones | 4.1 ± 11.0 | 4.9 ± 11.0 | 0.12 | 0.156 | 7.1 ± 15.0 | 4.2 ± 9.3 | −0.11 | 0.181 |
| Glycopeptides | 0.1 ± 0.6 | 0.3 ± 1.6 | 0.21 | 0.012 | 0.1 ± 0.5 | 0.4 ± 1.8 | 0.08 | 0.335 |
| Imidazole (metronidazole) | - | 0.5 ± 5.9 | 0.13 | 0.114 | - | 0.7 ± 6.8 | 0.05 | 0.566 |
| Macrolides | 0.1 ± 1.0 | 0.3 ± 2.6 | 0.12 | 0.142 | 0.2 ± 1.4 | 0.4 ± 2.9 | 0.02 | 0.794 |
| Sulfamethoxazole/trimethoprim | 3.1 ± 23.0 | 3.0 ± 20.0 | −0.01 | 0.918 | 0.9 ± 4.4 | 3.7 ± 22.9 | 0.06 | 0.481 |
| Tetracycline (doxycycline) | 0.8 ± 7.7 | - | −0.05 | 0.529 | 2.2 ± 13.0 | - | −0.15 | 0.083 |